Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
- PMID: 32646206
- PMCID: PMC7364356
- DOI: 10.3350/cmh.2020.0099
Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
Keywords: Chronic hepatitis B; Entecavir; Suboptimal response; Tenofovir.
Conflict of interest statement
Comment on
-
Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.Clin Mol Hepatol. 2020 Jul;26(3):352-363. doi: 10.3350/cmh.2019.0044n. Epub 2020 May 28. Clin Mol Hepatol. 2020. PMID: 32460460 Free PMC article. Clinical Trial.
References
-
- Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. - PubMed
-
- Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686. - PubMed
-
- European Association For The Study Of The Liver EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol. 2009;50:227–242. - PubMed
-
- Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–1722. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources